In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
For a short-term investment strategy, the company has poor fundamentals.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
According to forecast, a sluggish sales growth is expected for the next fiscal years.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The company's enterprise value to sales, at 4 times its current sales, is high.
With a 2018 P/E ratio at 27.94 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
For the past year, analysts have significantly revised downwards their profit estimates.
The underlying tendency is negative on the weekly chart below the resistance at 83.15 USD
Sector Medical Equipment, Supplies & Distribution - NEC